Literature DB >> 23558024

Managing pulmonary arterial hypertension and optimizing treatment options: prognosis of pulmonary artery hypertension.

Vallerie McLaughlin1.   

Abstract

Survival in patients with pulmonary artery hypertension has improved, but outcomes are still suboptimal. Therapeutic focus must shift from short-term functional changes to improvements in long-term outcomes. Several outcome predictors, both at baseline and on therapy, offer guidance for clinicians treating pulmonary artery hypertension.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23558024     DOI： 10.1016/j.amjcard.2013.01.319

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


  10 in total

1.  Sex differences in response to tadalafil in pulmonary arterial hypertension.

Authors:  Stephen C Mathai; Paul M Hassoun; Milo A Puhan; Yi Zhou; Robert A Wise
Journal:  Chest       Date:  2015-01       Impact factor: 9.410

2.  Computed tomography correlates with cardiopulmonary hemodynamics in pulmonary hypertension in adults with sickle cell disease.

Authors:  Marius George Linguraru; John A Pura; Mark T Gladwin; Antony I Koroulakis; Caterina Minniti; Roberto F Machado; Gregory J Kato; Bradford J Wood
Journal:  Pulm Circ       Date:  2014-06       Impact factor: 3.017

3.  An Update on Pulmonary Arterial Hypertension.

Authors:  Joanna Wapner; Lea Ann Matura
Journal:  J Nurse Pract       Date:  2015-05       Impact factor: 0.767

4.  Attenuation of monocrotaline-induced pulmonary hypertension by luminal adeno-associated virus serotype 9 gene transfer of prostacyclin synthase.

Authors:  Igor B Gubrij; Sara Rebecca Martin; Amanda K Pangle; Richard Kurten; Larry G Johnson
Journal:  Hum Gene Ther       Date:  2014-03-26       Impact factor: 5.695

5.  Calorie Restriction Attenuates Monocrotaline-induced Pulmonary Arterial Hypertension in Rats.

Authors:  Mingge Ding; Jingyi Lei; Yinxian Qu; Huan Zhang; Weichuan Xin; Feng Ma; Shuwen Liu; Zhichao Li; Faguang Jin; Enqing Fu
Journal:  J Cardiovasc Pharmacol       Date:  2015-06       Impact factor: 3.105

6.  VEGF Promoter Polymorphism Confers an Increased Risk of Pulmonary Arterial Hypertension in a Chinese Population.

Authors:  Yufeng Zhuo; Qingchun Zeng; Peng Zhang; Guoyang Li; Qiang Xie; Ying Cheng
Journal:  Yonsei Med J       Date:  2017-03       Impact factor: 2.759

Review 7.  Oxidative Stress and Its Implications in the Right Ventricular Remodeling Secondary to Pulmonary Hypertension.

Authors:  Matthew Mikhael; Christian Makar; Amir Wissa; Trixie Le; Mansoureh Eghbali; Soban Umar
Journal:  Front Physiol       Date:  2019-09-24       Impact factor: 4.566

8.  Long-term outcomes in pulmonary arterial hypertension by functional class: a meta-analysis of randomized controlled trials and observational registries.

Authors:  Nick H Kim; Micah Fisher; David Poch; Carol Zhao; Mehul Shah; Sonja Bartolome
Journal:  Pulm Circ       Date:  2020-11-25       Impact factor: 3.017

9.  A case report of a 37-year-old woman with pulmonary arterial hypertension first presented during her 3rd pregnancy and favourable long-term vasoreactive response.

Authors:  Julian Georg Westphal; Matthias Oehler; Paul Christian Schulze; Daniel Kretzschmar
Journal:  Eur Heart J Case Rep       Date:  2022-02-07

Review 10.  Cardiac magnetic resonance findings predicting mortality in patients with pulmonary arterial hypertension: a systematic review and meta-analysis.

Authors:  Vivan J M Baggen; Tim Leiner; Marco C Post; Arie P van Dijk; Jolien W Roos-Hesselink; Eric Boersma; Jesse Habets; Gertjan Tj Sieswerda
Journal:  Eur Radiol       Date:  2016-02-04       Impact factor: 5.315
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.